Analyst Price Targets — GHRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 10:40 am | Eddie Hickman | Guggenheim | $34.00 | $15.81 | StreetInsider | GH Research PLC (GHRS) PT Raised to $34 at Guggenheim |
| March 6, 2026 12:04 pm | Ami Fadia | Needham | $32.00 | $15.34 | StreetInsider | GH Research PLC (GHRS) PT Raised to $32 at Needham |
| January 23, 2026 7:24 pm | — | RBC Capital | $40.00 | $16.73 | TheFly | GH Research price target raised to $40 from $33 at RBC Capital |
| January 6, 2026 12:40 pm | — | Needham | $29.00 | $15.46 | TheFly | GH Research price target raised to $29 from $19 at Needham |
| January 6, 2026 11:24 am | — | Canaccord Genuity | $39.00 | $15.46 | TheFly | GH Research price target raised to $39 from $35 at Canaccord |
| January 6, 2026 10:05 am | — | Wolfe Research | $39.00 | $15.46 | StreetInsider | GH Research (GHRS) Reiterated at Market Outperform by Citizens on GH001 Potential |
| January 5, 2026 2:59 pm | Eddie Hickman | Guggenheim | $29.00 | $15.80 | StreetInsider | Guggenheim Reiterates Buy Rating on GH Research PLC (GHRS) Post Mgmt Call |
| November 10, 2025 4:07 pm | Patrick Trucchio | H.C. Wainwright | $35.00 | $13.55 | TheFly | GH Research price target lowered to $35 from $40 at H.C. Wainwright |
| October 13, 2025 10:05 am | — | Needham | $19.00 | $12.59 | TheFly | GH Research initiated with a Buy at Needham |
| November 18, 2024 12:10 pm | Sumant Kilkami | Canaccord Genuity | $28.00 | $9.26 | StreetInsider | GH Research PLC (GHRS) PT Lowered to $28 at Canaccord Genuity |
Latest News for GHRS
Prenetics Global (NASDAQ: PRE - Get Free Report) and GH Research (NASDAQ: GHRS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability. Analyst Ratings This is a summary of
DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression (TRD): the primary trial results in JAMA Psychiatry , and a new…
GH Research PLC remains well-capitalized with $280.7 million in cash, supporting its lead candidate GH001 for Treatment-Resistant Depression. GHRS's investment thesis centers on replicating strong Phase 2b efficacy for GH001 in a pivotal Phase 3 trial, with rapid, durable antidepressant effects and operational simplicity. The FDA has cleared GH001 for U.S. clinical investigation, positioning GHRS for a global Phase…
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025 DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GHRS.
U.S. House Trading
No House trades found for GHRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.